Perioperative management of anticoagulant users scheduled for glaucoma surgery: a survey among the Brazilian Glaucoma Society members

Marcos BalBino1,2, Plinio Boin3, Tiago Santos Prata2,3

ABSTRACT

Purpose: To investigate and describe, among the members of the Brazilian Glaucoma Society (BGS), the practices regarding the perioperative management of anticoagulants (warfarin and aspirin) use in patients scheduled for glaucoma surgery.

Methods: The active members of the Brazilian Glaucoma Society answered a questionnaire evaluating different aspects of their current perioperative management of glaucomatous patients taking warfarin or aspirin.

Results: A total of 52 participants returned a complete questionnaire. Warfarin or aspirin was routinely interrupted prior to glaucoma surgery by 82.7% of the respondents. The majority of the surgeons who discontinued these medications reported doing so 7 days prior to surgery and resumed their use the day after the procedure. Almost half of our interviewees reported hemorrhagic complications that could be related to anticoagulant therapy. A large number of the surgeons (86.5%) preferred a particular surgical technique for anticoagulated patients; however, most of them (88.5%) do not change the anesthetic planning in such patients. Finally, the majority of the participants (90.4%) refer their anticoagulated patients to a preoperative appointment with a cardiologist or a general practitioner before the surgery.

Conclusions: The majority of Brazilian Glaucoma Society members participating in this study interrupt either warfarin or aspirin prior to glaucoma surgery. Although there is scant information available in the literature to offer definitive guidance, most participants from the Brazilian Glaucoma Society seem to share the same opinion when it comes to perioperative management of anticoagulant users.

Keywords: Anticoagulants/adverse effects; Aspirin; Warfarin; Glaucoma/surgery; Cataract extraction; Perioperative period; Societies, medical; Questionnaires

INTRODUCTION

Prophylactic anticoagulation has been of paramount importance in preventing coronary ischemic events, stroke and peripheral arterial obstruction. Moreover, since the advent of coronary stenting, these drugs have become fundamental as adjuvants to this invasive approach to coronary disorders. Each year, anticoagulant therapy is used to protect millions of cardiac patients from direct artery obstruction or reocclusion after implanting a stent1,2. On the other hand, it is well known that anticoagulated patients are exposed to a greater risk of hemorrhages when submitted to incisional surgeries3,4.

The general perioperative management of anticoagulated patients has been described previously in details5,6. In ophthalmological surgeries, there are some data postulating the safety in maintaining anticoagulants before cataract surgery7,8; however, there is little information available to offer definitive guidance in glaucoma surgery9,10, as well as in retina surgery11,12.

The purpose of the present study was to evaluate the current routine of glaucoma surgeons in Brazil regarding the use of anticoagulants in patients scheduled for glaucoma surgery. The study was based on data collected from the members of the Brazilian Glauco-
Anticoagulation was not a reason for choosing a specific anesthetic planning to the vast majority of the surgeons, as 47 (90.4%) of them did not change their usual anesthesia procedure. According to the participants, 38 (73.1%) preferred injectable anesthesia while 12 (23.1%) preferred topical anesthesia and only two (3.8%) chose general anesthesia. The surgical procedure itself can vary according to the presence of anticoagulants: 45 participants (86.5%) preferred a particular incision type in these patients, whereas 7 (13.5%) did not change their technique. Finally, the majority of the participants (90.3%) referred their anticoagulated patients to a preoperative appointment with a cardiologist or a general practitioner prior to the surgery.

DISCUSSION

The perioperative management of patients who require temporary interruption of vitamin K antagonists or antiplatelet drugs because of a surgical procedure is a common and challenging clinical problem [2]. The number of such patients has increased over the last decade, due to cardiovascular diseases (atrial fibrillation; mechanical heart valve) or percutaneous coronary intervention; therefore, these patients are no longer the tiny minority of the non-cardiac surgical candidates. A multicenter audit has shown that 28.1% and 5.1% of 48,862 patients submitted to cataract surgery were taking aspirin or warfarin, respectively [8].

The rare occurrence of serious hemorrhagic complications with visual impairment in patients who keep aspirin or warfarin throughout the perioperative period has been shown before [23,24]. An Evidence-Based Clinical Practice Guideline suggested (a Grade 1C recommendation) that patients undergoing cataract extraction who are under warfarin or aspirin should continue their anticoagulants around the time of the procedure [25]. Anticoagulants were also advised to be maintained even in cases of 25-gauge vitrectomy, in which the frequency of serious hemorrhagic complications were extremely low [26]. Unfortunately, there are scant data available for such patients when it comes to glaucoma surgery.

In a previous survey done in the United Kingdom, questionnaires were sent to ophthalmologists with a special interest in glaucoma [27]. Approximately 30% of the respondents stop either warfarin or aspirin, for 4 and 7 days prior to surgery, respectively. These numbers are significantly lower when compared to the responses of most of the participants from our study, as over 80% are prone to interrupt both drugs, and most of them do so for seven days before surgery. We believe the main reason for this difference could be related to the fact that a significant percentage of the participants in our study (approximately half of them) have experienced hemorrhagic complications in their anticoagulated patients during or after a glaucoma surgery. Another interesting difference between these two studies is that while most of the interviewees in our study (over 90%) required a cardiologist or a general practitioner opinion when dealing with anticoagulated patients prior to glaucoma surgery (even though there is no official guideline for this), only 23.8% of the respondents from the British survey [23] usually rely on a second opinion (in fact, an hematologist was the specialist required in that study).

We found that the majority of BGS members interviewed preferred injectable anesthesia. A large study analyzed more than 14,000 peribulbar/retrolubular anesthetics in a cohort where 24.2% and 4% of the patients were on aspirin or warfarin, respectively. Hemorrhage rate in that study due to the anesthesia was found to be extremely low [26]. However, as discussed previously, not only anesthesia related hemorrhages can occur in anticoagulated patients, but also those related to the surgical manipulation itself. The later seem to be even more important in these cases, as approximately half of the BGS members interviewed reported some type of hemorrhagic complication (from subconjunctival hemorrhage to choroidal detachment). In this context, a previous report has alerted to the risk of excessive

### RESULTS

A total of 52 participants returned a complete questionnaire, resulting in a response rate of approximately 13%.

When asking about interrupting anticoagulation drugs, 82.7% (42 out of 52) said they interrupted both aspirin and warfarin before operating on these patients, and the remaining 17.3% (9 out of 52) kept such medications throughout the perioperative period. Among those who interrupted anticoagulants, the majority (36 out of 52, corresponding to 69.2%) did so seven days before surgery, interrupting both aspirin and warfarin. Three participants (5.8%) interrupted anticoagulants for 10 days, and one (1.9%) did so for 15 days. Finally, three (5.8%) suspended the drugs for up to 5 days before the procedure (Table 1). Regarding the participants who suspended the anticoagulants, most of them resumed such drugs in the following manner: 24 (55.8%) reintroduced the drugs 1 day after the procedure, 4 (9.3%) after 2-5 days, and 9 (20.9%) after 7 days.

Twenty-seven respondents (51.9%) experienced hemorrhagic complications that may have been related to anticoagulation therapy. There were participants who reported more than one hemorrhagic event. Among them, 8 (29.6%) reported the occurrence of excessive subconjunctival hemorrhage (one of them noticed hemorrhage at the filtration bleb); 7 (25.9%) reported the occurrence of hyphema, 8 (29.6%) described cases of increased postoperative bleeding and two (7.4%) reported a hemorrhagic choroidal detachment. There were three reports (11.1%) of hemorrhage related to the needle-based eye block.

### Table 1. Routine anticoagulation management prior to glaucoma surgery

<table>
<thead>
<tr>
<th>Anticoagulation management</th>
<th>Percentage of participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withold treatment 10 days or more before surgery</td>
<td>7.7% (4/52)</td>
</tr>
<tr>
<td>Withold treatment 7 days before surgery</td>
<td>69.2% (36/52)</td>
</tr>
<tr>
<td>Withold treatment up to 5 days before surgery</td>
<td>5.8% (3/52)</td>
</tr>
<tr>
<td>Do not withhold anticoagulant therapy</td>
<td>17.3% (9/52)</td>
</tr>
</tbody>
</table>
harmorrhage during glaucoma surgery in anticoagulated patients, especially in those taking warfarin\(^{(11)}\).

The main drawback of our paper is its low response rate (13%) and number of participants (n=52), which should be considered while interpreting our results. Looking carefully at the related literature, response rates of ophthalmological surveys seem to vary significantly. For instance, while a small survey among cataract surgeons in Singapore reported a response rate of 61%\(^{(12)}\), a large study in the USA among the American Society of Cataract and Refractive Surgery (ASCRS) members had a much lower rate, of approximately 15%\(^{(13)}\). Interestingly, the later study is a traditional survey, which had been applied and reported annually since 1985\(^{(14)}\). We believe that different factors might have partially contributed to the low response rate we have obtained. First, glaucoma specialists in general could not be used to this type of surgical survey. While there are many previously published surgical surveys among cataract surgeons, a significant proportion of the surveys among glaucoma specialists have focused on the clinical management of the disease (drug preferences), and not on surgical preferences. Second, this type of study design is not a usual practice in Brazil, as there are few publications available in the ophthalmological literature based on questionnaire responses (surveys). In addition, some of the participants could not be familiar or even comfortable while dealing with an Internet based approach. Third, differently from cataract specialists, not every glaucoma specialist performs surgical procedures. We believe that a significant proportion of the BGS members might not be composed by active glaucoma surgeons. Finally, two other aspects or limitations of our study should be considered as they might have influenced our results. We assessed the management of anticoagulants considering warfarin and aspirin in conjuction. Therefore, we could not determine whether a respondent would have a different approach for each anticoagulant drug. In addition, due to the study design (Survey), glaucoma specialists that had previous hemorrhagic complications usually tend to participate more than those who never experienced such problems. This fact (bias) might have increased the percentage of hemorrhagic events reported in our study.

CONCLUSION

In sum, the majority of the BGS members interviewed interrupt anticoagulant drugs before a glaucoma surgery. Most of the ophthalmologists withhold either warfarin or aspirin for seven days. Ninety percent require a cardiologist or a general practitioner opinion prior to the surgery. Hemorrhagic surgical complications were reported by approximately half of the interviewees. Currently, the management of anticoagulated patients scheduled for glaucoma surgery has no specific recommendation. Possibly, these patients are exposed to a higher risk, and further studies are necessary to establish a definitive medical management protocol.

REFERENCES